The cancer vaccine field is being driven by a mix of large pharmaceutical companies and smaller biotech firms, with BioNTech and Moderna leading the charge on mRNA-based platforms, while dozens of other companies pursue dendritic cell vaccines, viral vectors, neoantigen-targeting strategies, and in situ approaches. The landscape has expanded rapidly since COVID-19 proved that mRNA technology could be manufactured at scale, and the result is a crowded, fast-moving space where fully personalized vaccines compete with off-the-shelf designs for clinical traction. Understanding who is doing what, and how their approaches differ, takes more than a list of company names.
How Cancer Vaccines Differ From the Vaccines You Already Know
Most people think of vaccines as something you get before you are sick, like a flu shot or an MMR booster. That model does exist in cancer, but it is the minority. Preventive cancer vaccines target viruses known to cause cancer. The HPV vaccine, for instance, prevents infections that lead to cervical and other cancers, and the hepatitis B vaccine reduces the incidence of liver cancer. These are already widely used and well established.
The vaccines generating the most excitement right now are therapeutic: they are given to people who already have cancer. The goal is to train the immune system to recognize and attack tumor cells by activating specific immune responses against tumor-specific targets. That is a fundamentally harder problem than preventing a viral infection, because tumors are made of the patient’s own cells and have evolved ways to hide from immune detection.
The mRNA Vaccine Leaders
BioNTech and Moderna are the most visible names in the cancer vaccine space, largely because their COVID-19 vaccines demonstrated that mRNA technology works in humans at massive scale. Both companies have pivoted aggressively into oncology.
BioNTech’s lead cancer vaccine candidate is called cevumeran (also known as autogene cevumeran or BNT122). It is a personalized mRNA vaccine designed to target neoantigens, which are mutated proteins unique to an individual patient’s tumor. In practice, this means that after a tumor is surgically removed, its DNA is sequenced, the most promising mutations are identified, and a custom mRNA vaccine is manufactured for that specific patient. BioNTech has been testing cevumeran in combination with the checkpoint inhibitor atezolizumab in pancreatic cancer, among other tumor types.
Moderna’s parallel program centers on mRNA-4157, also called V940, which it has developed in partnership with Merck. This vaccine similarly targets patient-specific neoantigens and has been tested most prominently in melanoma alongside pembrolizumab, a widely used checkpoint inhibitor. Early clinical results generated significant attention because of signals that the vaccine reduced the risk of cancer recurrence after surgery.
Beyond these two Western companies, several Chinese firms are pursuing mRNA cancer vaccines, including Stemirna Therapeutics, NeoCura, and Hangzhou Neoantigen Therapeutics, reflecting a broader global push in the space.1Siberian journal of oncology. Antitumor mRNA vaccines based on neoantigens The field is not a two-company race. It is a global effort with dozens of clinical-stage programs.
Personalized Vaccines Versus Off-the-Shelf Designs
One of the biggest strategic divides in the cancer vaccine world is between personalized and generalized approaches. A personalized vaccine, like BioNTech’s cevumeran, is built from scratch for each patient. That gives it the theoretical advantage of targeting the exact mutations in that patient’s tumor, but it comes with serious practical drawbacks: manufacturing takes weeks, costs are high, and the process requires specialized sequencing and bioinformatics infrastructure.
Off-the-shelf vaccines use antigens shared across many patients’ tumors. These are faster to produce and easier to distribute, but they may miss the mutations that make a particular patient’s cancer most vulnerable. A growing middle category uses semi-personalized approaches, where a vaccine is assembled from a library of pre-made components based on which mutations a patient’s tumor carries.
A review of mRNA vaccine candidates in clinical development found that only about a third of programs targeting non-communicable diseases like cancer were fully generalized. Roughly another third were semi-personalized, and about a quarter were fully personalized, reflecting the field’s strong lean toward tailored strategies.2PubMed Central. mRNA vaccines and therapeutics beyond COVID-19: A review of the global clinical development landscape, low- and middle-income countries involvement and relevance to their contexts The trend suggests that companies see personalization as worth the extra complexity, at least for now.
Dendritic Cell Vaccines and Their Complicated Track Record
Before mRNA vaccines grabbed the spotlight, dendritic cell vaccines were the most prominent therapeutic cancer vaccine platform. Dendritic cells are the immune system’s scouts: they capture foreign or abnormal proteins, process them, and present them to T cells to trigger an immune attack. The idea behind a dendritic cell vaccine is to take a patient’s own dendritic cells, load them with tumor antigens in a lab, and then inject them back into the patient to jump-start an anti-tumor response.
Sipuleucel-T, marketed as Provenge and developed by Dendreon, became the first FDA-approved therapeutic cancer vaccine in 2010. It was approved for metastatic prostate cancer after showing an improvement in overall survival. But despite that milestone, the story since then has been frustrating. Further dendritic cell vaccines have largely failed to progress through clinical development, and uptake of sipuleucel-T itself in the clinic has been limited.3PubMed. Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer The manufacturing process was cumbersome, requiring each patient’s blood to be shipped to a central facility and processed individually, and the survival benefit, while real, was modest enough that many oncologists opted for other treatments.
Researchers have been working on next-generation dendritic cell vaccines that use improved antigen-loading technologies, including nanoparticles, antibody-antigen conjugates, and virus co-delivery systems, to make the approach more potent.3PubMed. Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer Several smaller biotech companies continue to work in this space, though the momentum has clearly shifted toward mRNA and neoantigen-based approaches.
Viral Vector and DNA Platforms
Viral vector vaccines use a modified, harmless virus to deliver genetic instructions for tumor antigens into the body. The viral carrier infects cells, those cells produce the tumor antigen, and the immune system mounts a response against it. DNA plasmid vaccines work on a similar principle but use a small circular piece of DNA instead of a virus to deliver the instructions. Both platforms have been explored extensively in cancer because they tend to provoke strong immune responses and can be engineered to carry multiple antigens at once.4PubMed. Plasmid DNA and viral vector-based vaccines for the treatment of cancer
Companies working in this space include Inovio Pharmaceuticals, which has developed DNA-based cancer vaccines for cervical dysplasia and other conditions, and Geneos Therapeutics, which combines DNA vaccines with electroporation technology. Advaxis (now Ayala Pharmaceuticals) pursued a Listeria-based vector approach targeting HPV-related cancers. The viral vector approach overlaps with the gene therapy world, and some companies straddle both fields. While these platforms have not yet produced a blockbuster cancer vaccine, they remain active in clinical trials and are often used in combination strategies alongside checkpoint inhibitors.
In Situ Vaccination: Turning the Tumor Into Its Own Vaccine
One of the more creative strategies sidesteps the manufacturing challenge entirely. In situ vaccination involves injecting immunostimulatory agents directly into a tumor, turning it into a kind of endogenous vaccine platform. The idea is that by triggering a strong immune response inside the tumor, the immune system learns to recognize the tumor’s antigens on its own, without anyone needing to sequence or manufacture anything. The tumor itself becomes the source of antigens.5Signal Transduction and Targeted Therapy. Combinatorial in situ cancer vaccines: unlocking broad and enhanced antitumor responses
This approach has been explored using a variety of off-the-shelf immunomodulators, including toll-like receptor agonists, oncolytic viruses, and cytokines, all injected directly into accessible tumors.6PubMed Central. In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf Companies pursuing in situ approaches include Checkmate Pharmaceuticals (acquired by Regeneron), which worked on a CpG oligonucleotide called vidutolimod, and Replimune, which uses an oncolytic virus platform. The appeal is that in situ vaccines are inherently personalized (they use whatever antigens are in the patient’s tumor) without requiring the expense and delay of custom manufacturing. The limitation is that they typically require an injectable tumor, which restricts their use to cancers with accessible lesions.
Cancer Prevention Beyond HPV: The Lynch Syndrome Story
While most therapeutic cancer vaccine development targets existing tumors, a small but fascinating branch of research is working on vaccines that prevent cancer in high-risk individuals who do not yet have it. The most advanced example targets Lynch syndrome, a hereditary condition that dramatically increases the risk of colorectal, endometrial, and several other cancers.
People with Lynch syndrome carry mutations in DNA mismatch repair genes, which means their cells accumulate a specific type of mutation called frameshift peptides. These predictable mutations create neoantigens that can be targeted by a vaccine before cancer even develops. Several groups have designed vaccines composed of commonly recurring frameshift peptide neoantigens, selected through prediction algorithms, and have shown these to be safe and capable of triggering immune responses in Lynch syndrome carriers.7PubMed Central. Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies
Nouscom, an Italian-Swiss biotech company, has taken this furthest with its Nous-209 vaccine. In a phase 1b/2 trial of 45 Lynch syndrome carriers, vaccination was safe and produced neoantigen-specific immune responses in all evaluable participants. The most common side effects were injection-site reactions and fatigue, with no serious adverse events related to the treatment.8Nature Medicine. Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial Whether that immune response actually prevents cancers from forming will take longer to determine, but the concept of “cancer interception,” vaccinating against cancer in people at high genetic risk before tumors appear, is one of the more genuinely novel ideas in the field.
How AI Is Reshaping Vaccine Design
Designing a personalized cancer vaccine requires solving a computational puzzle: which of the hundreds or thousands of mutations in a patient’s tumor are most likely to provoke a useful immune response? Not every mutation makes a good vaccine target. The mutated protein needs to be processed by the cell, presented on its surface, and recognized by T cells. Predicting which mutations clear all those hurdles is where artificial intelligence has become increasingly central to the field.
Machine learning and deep learning models now integrate data on how well peptides bind to the molecules that display them on cell surfaces, how efficiently the cell processes those peptides, and how likely T cell receptors are to recognize them.9BioChem. Advances in Personalized Cancer Vaccine Development: AI Applications from Neoantigen Discovery to mRNA Formulation AI is also being used to optimize the mRNA and DNA sequences in vaccines themselves, and to predict how individual patients might respond to specific vaccine designs.10PubMed Central. Personalized cancer vaccine design using AI-powered technologies
Companies like BioNTech and Gritstone bio (now part of Gritstone) have built proprietary AI platforms specifically for neoantigen prediction. The better these algorithms get, the faster a personalized vaccine can be designed and the more likely it is to contain targets that actually trigger a strong immune response. This is one of those areas where incremental improvements in software can translate directly into better clinical outcomes, and it is a major reason why tech-heavy biotech firms have poured resources into the space.
The Tumor Microenvironment Problem
Even a well-designed cancer vaccine faces a formidable obstacle once the immune response it generates reaches the tumor. Tumors are not passive targets. They actively create a local environment that suppresses immune activity, essentially building a shield around themselves. This immunosuppressive microenvironment can blunt T cell responses and allow the tumor to develop resistance even to therapies that initially work.11Frontiers in Immunology. Global trends in tumor microenvironment-related research on tumor vaccine: a review and bibliometric analysis
This is why so many cancer vaccine trials combine the vaccine with a checkpoint inhibitor. Checkpoint inhibitors are drugs that release the brakes the tumor has placed on the immune system. The vaccine provides the target, the checkpoint inhibitor clears the path. The BioNTech and Moderna programs described earlier both rely on this combination strategy. It also explains why cancer vaccines alone have historically underperformed expectations: the vaccine might successfully train T cells to recognize the tumor, but those T cells can be rendered useless if the tumor’s microenvironment shuts them down before they can act.
Delivery Technology and the Nanoparticle Frontier
Getting the vaccine’s payload to the right part of the body is a challenge that matters almost as much as choosing the right antigens. For mRNA cancer vaccines, this means using lipid nanoparticles, the same tiny fat bubbles that delivered the COVID-19 mRNA vaccines. But cancer vaccines have a more specific targeting need: they work best when the mRNA reaches the lymph nodes, where immune cells are concentrated and can be activated most efficiently.
Researchers have been developing lipid nanoparticles specifically designed to accumulate in the lymph nodes. In one study, a nanoparticle formulation called 113-O12B delivered mRNA to the lymph nodes more effectively than the lipid used in the Pfizer-BioNTech COVID-19 vaccine, and this targeted delivery translated into a stronger T cell response against the encoded antigen.12PubMed Central. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8(+) T cell response This kind of delivery optimization is happening across many companies and academic groups, and it represents one of the less visible but potentially high-impact areas of cancer vaccine development. A vaccine with mediocre antigens delivered perfectly to the immune system might outperform a vaccine with perfect antigens that mostly ends up in the liver.
The Cost and Access Challenge
Personalized cancer vaccines are, almost by definition, expensive. Each one requires tumor sequencing, bioinformatic analysis, custom manufacturing, and quality testing, all for a single patient. That economic reality raises hard questions about who will be able to access these treatments and who will pay for them.
Public reimbursement is critical for market access, and the methodology for evaluating the cost-effectiveness of cancer vaccines is complicated. Preventive vaccines like the HPV vaccine are evaluated differently from therapeutic vaccines given to patients with active cancer, and the frameworks used for other cancer drugs do not always translate well.13PubMed Central. Cancer vaccines and immunotherapeutics: challenges for pricing, reimbursement and market access A therapeutic cancer vaccine might extend survival by months rather than years, and the question of whether that benefit justifies a six-figure price tag is one that health systems around the world will need to answer repeatedly as these products move toward approval.
Off-the-shelf approaches could eventually reduce costs, since a single vaccine design could be manufactured at scale for many patients. But the field’s current enthusiasm for personalization means that the most advanced programs are also the most expensive ones. Some companies are betting that manufacturing efficiencies will bring costs down over time, much as the cost per genome sequenced has dropped precipitously over the past two decades. Whether that optimism is warranted remains to be seen.
Who Gets Into Clinical Trials
Most cancer vaccine candidates are still in clinical trials, which means that for now, the main way to access them is by enrolling in a study. That creates its own set of problems. Clinical trials in oncology are disproportionately concentrated in resource-rich countries and tend to enroll participants who are younger, healthier, more educated, and more likely to be white than the broader population of cancer patients.14PubMed Central. Equitable inclusion of diverse populations in oncology clinical trials: deterrents and drivers This matters not just for equity but for the science: if vaccines are only tested in narrow populations, the results may not generalize well to the diverse patient populations who would eventually use them.
For patients interested in cancer vaccine trials, ClinicalTrials.gov remains the most comprehensive registry. Eligibility criteria vary widely, and many trials require specific tumor types, stages, or prior treatment histories. Some trials are limited to patients whose tumors have been sequenced and found to carry certain mutation profiles, which adds another layer of access complexity. Advocacy organizations for specific cancer types often maintain curated lists of open trials and can help patients navigate the enrollment process.
The Long Road From Lab to Clinic
Cancer vaccine development has been pursued intensively for over fifty years, and for most of that time, results were disappointing. The immune system’s tolerance of tumor cells, the difficulty of choosing the right antigens, and the suppressive tumor microenvironment all conspired to produce clinical trial after clinical trial with underwhelming results.15PubMed Central. Evolution of Cancer Vaccines-Challenges, Achievements, and Future Directions What has changed in recent years is not any single breakthrough but the convergence of several advances: better genomic sequencing, AI-powered antigen selection, proven mRNA delivery platforms, and a deeper understanding of how the tumor microenvironment works.
That convergence does not guarantee success. The history of cancer immunotherapy is littered with promising early-phase results that did not hold up in larger trials. But the number and diversity of companies now working on cancer vaccines, spanning mRNA, dendritic cell, viral vector, DNA, neoantigen, and in situ approaches across dozens of tumor types, is unprecedented. Preventive vaccines that reduce the incidence of virus-associated cancers are already among the most successful public health interventions in history.16PubMed Central. Cancer vaccines: platforms and current progress Whether therapeutic vaccines can eventually match that impact is the question driving a generation of researchers, and a great deal of investor money, forward.